top of page

Myeloperoxidase (MPO) Antibody

Ordering Recommendation

When used in conjunction with other autoantibody tests (ANCA, PR3), may aid in evaluating suspected immune-mediated vasculitis, especially microscopic polyangiitis (MPA). May be useful to monitor MPA disease and/or treatment response.

Panel tests are available. For the workup of suspected vasculitis, refer to ANCA-Associated Vasculitis Profile (ANCA/MPO/PR3) (3003745). For patients with a history of vasculitis, refer to Myeloperoxidase (MPO) Antibody and Serine Proteinase 3 (PR3) Antibody with Reflex to Anti-Neutrophil Cytoplasmic Antibody, IgG by IFA (3003746).

Mnemonic
MPO-AB
Performed
Mon-Sat
Methodology
Semi-Quantitative Multiplex Bead Assay
Reported
1-3 Days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation:
Collect:
Serum separator tube. 
Specimen Preparation:
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to a Standard Transport Tube. (Min: 0.2 mL)
Storage/Transport Temperature:
Refrigerated.
Unacceptable Conditions:
Plasma, urine, or other body fluids.  Contaminated, hemolyzed, or severely lipemic specimens., icteric, or lipemic specimens.
Remarks:
Stability:
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Reference Interval
19 AU/mL or less
Negative
20-25 AU/mL
26 AU/mL or greater
Equivocal
Positive
Interpretive Data
Approximately 90% of patients with a P-ANCA pattern by IFA have antibodies specific for MPO.
Compliance Category: FDA
Note
CPT Code
83516
Components
Component Chart Name
Myeloperoxidase (MPO) Ab, IgG
Component Test Code
0050526
LOINC
6969-0
Aliases
MPO
MPO Ab
PR3
bottom of page